The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block listing Interim Review

17 Aug 2016 08:56

RNS Number : 4133H
GW Pharmaceuticals PLC
17 August 2016
 

 

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS APPROVED SHARE OPTION SCHEME 2001

 

3. PERIOD OF RETURN:

 

FROM: 18 FEBRUARY 2016 TO: 17 AUGUST 2016

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

42,400 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

17,000 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

25,400 ORDINARY SHARES OF 0.1P EACH

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

516,558 ORDINARY SHARES OF 0.1P EACH ON 21 JULY 2004

200,000 ORDINARY SHARES OF 0.1P EACH ON 23 FEBRUARY 2011

200,000 ORDINARY SHARES OF 0.1P EACH ON 29 NOVEMBER 2013

122,613 ORDINARY SHARES OF 0.1P EACH ON 9 JUNE 2014

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

301,779,915 ORDINARY SHARES OF 0.1P EACH

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS UNAPPROVED SHARE OPTION SCHEME 2001

 

3. PERIOD OF RETURN:

 

FROM: 18 FEBRUARY 2016 TO: 17 AUGUST 2016

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

144,737 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

0 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

144,737 ORDINARY SHARES OF 0.1P EACH

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

1,279,192 ORDINARY SHARES OF 0.1P EACH ON 21 JULY 2004

500,000 ORDINARY SHARES OF 0.1P EACH ON 24 MAY 2011

800,000 ORDINARY SHARES OF 0.1P EACH ON 29 NOVEMBER 2013

500,000 ORDINARY SHARES OF 0.1P EACH ON 9 JUNE 2014

500,000 ORDINARY SHARES OF 0.1P EACH ON 9 JANUARY 2015

500,000 ORDINARY SHARES OF 0.1P EACH ON 5 JUNE 2015

741,558 ORDINARY SHARES OF 0.1P EACH ON 8 SEPTEMBER 2015

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

301,779,915 ORDINARY SHARES OF 0.1P EACH

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS EXECUTIVE SHARE OPTION SCHEME

 

3. PERIOD OF RETURN:

 

FROM: 18 FEBRUARY 2016 TO: 17 AUGUST 2016

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

200,250 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

0 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

200,250 ORDINARY SHARES OF 0.1P EACH.

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

1,388,375 ORDINARY SHARES OF 0.1P EACH ON 7 OCTOBER 2003

300,000 ORDINARY SHARES OF 0.1P EACH ON 23 APRIL 2008

400,000 ORDINARY SHARES OF 0.1P EACH ON 18 JANUARY 2010

400,000 ORDINARY SHARES OF 0.1P EACH ON 23 FEBRUARY 2011

300,000 ORDINARY SHARES OF 0.1P EACH ON 24 MAY 2011

168,650 ORDINARY SHARES OF 0.1P EACH ON 9 JUNE 2014

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

301,779,915 ORDINARY SHARES OF 0.1P EACH

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS LONG TERM INCENTIVE PLAN 2008

 

3. PERIOD OF RETURN:

 

FROM: 18 FEBRUARY 2016 TO: 17 AUGUST 2016

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

647,071 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

497,229 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

1,149,842 ORDINARY SHARES OF 0.1P EACH.

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

600,000 ORDINARY SHARES OF 0.1P EACH ON 23 FEBRUARY 2011

300,000 ORDINARY SHARES OF 0.1P EACH ON 29 NOVEMBER 2013

500,000 ORDINARY SHARES OF 0.1P EACH ON 9 JUNE 2014

1,000,000 ORDINARY SHARES OF 0.1P EACH ON 5 JUNE 2015

758,442 ORDINARY SHARES OF 0.1P EACH ON 8 SEPTEMBER 2015

1,000,000 ORDINARY SHARES OF 0.1P EACH ON 18 MARCH 2016

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

301,779,915 ORDINARY SHARES OF 0.1P EACH

 

 

 

For further information, please contact:

 

Adam George, Company Secretary, GW Pharmaceuticals plc

 

Telephone: +44 (0)1223 266800

 

James Steel/Oliver Jackson, Nominated Adviser, Peel Hunt LLP

 

Telephone: +44 (0)20 7418 8900

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRGRGDIUUBBGLR
Date   Source Headline
1st Dec 201611:15 amRNSAmerican Society of Epilepsy Annual Meeting
30th Nov 20161:00 pmRNSNotice of Q4 and year-end results
24th Nov 20167:30 amRNSHolding(s) in Company
22nd Nov 20161:00 pmRNSPresenting at Piper Jaffray Healthcare Conference
18th Nov 20169:31 amRNSHolding(s) in Company
11th Nov 20165:01 pmRNSHolding(s) in Company
10th Nov 201611:03 amRNSDirector/PDMR Shareholding
3rd Nov 20161:58 pmRNSDirector/PDMR Shareholding
3rd Nov 20167:50 amRNSHolding(s) in Company
3rd Nov 20167:47 amRNSHolding(s) in Company
2nd Nov 20165:05 pmRNSDirector/PDMR Shareholding
1st Nov 20169:58 amRNSDirector/PDMR Shareholding
31st Oct 20163:29 pmRNSHolding(s) in Company
31st Oct 20162:59 pmRNSTotal Voting Rights
31st Oct 20168:25 amRNSHolding(s) in Company
28th Oct 20164:58 pmRNSDirector Stock Trading Plan
28th Oct 20164:57 pmRNSDirector/PDMR Shareholding
26th Oct 20165:26 pmRNSDirector/PDMR Shareholding
25th Oct 20165:43 pmRNSDirector/PDMR Shareholding
21st Oct 20164:37 pmRNSPosting of Shareholder Circular
20th Oct 20163:30 pmRNSHolding(s) in Company
19th Oct 20167:00 amRNSIntention to Trade Exclusively on NASDAQ
7th Oct 201610:22 amRNSDirector Stock Trading Plan - Replacement
6th Oct 20166:01 pmRNSDirector Stock Trading Plan
30th Sep 20161:48 pmRNSTotal Voting Rights
26th Sep 201611:57 amRNSSecond Positive Phase 3 Trial for Epidiolex in LGS
14th Sep 20165:27 pmRNSDirector/PDMR Shareholding
7th Sep 201612:00 pmRNSPresenting at Morgan Stanley Healthcare Conference
31st Aug 201612:18 pmRNSTotal Issued Share Capital
17th Aug 20168:56 amRNSBlock listing Interim Review
9th Aug 201612:00 pmRNS3rd Quarter Results
9th Aug 201612:00 pmRNSNotification of Future Change to Board
2nd Aug 201612:00 pmRNSNotice of Results
29th Jul 201610:58 amRNSTotal Voting Rights
25th Jul 20167:57 amRNSHolding(s) in Company
21st Jul 201610:08 amRNSHolding(s) in Company
21st Jul 201610:04 amRNSHolding(s) in Company
19th Jul 20169:37 amRNSTotal Voting Rights
18th Jul 20164:15 pmRNSClosing of U.S. Public Offering Raising $289.8m
13th Jul 20167:00 amRNSUS Public Offering of ADSs Raising $252.0 Million
13th Jul 20167:00 amRNSProposed Public Offering of ADSs
1st Jul 20163:14 pmRNSHolding(s) in Company
1st Jul 20168:03 amRNSHolding(s) in Company
30th Jun 20163:22 pmRNSTotal Voting Rights
28th Jun 201612:14 pmRNSHolding(s) in Company
27th Jun 201612:07 pmRNSSecond Price Monitoring Extn
27th Jun 201612:02 pmRNSPrice Monitoring Extension
27th Jun 201612:00 pmRNSPositive Phase 3 Pivotal Trial Results
27th Jun 201610:00 amRNSHolding(s) in Company
23rd Jun 20167:30 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.